Literature DB >> 33462753

Skin barrier dysfunction and filaggrin.

Yeonjoon Kim1, Kyung-Min Lim2.   

Abstract

Skin barrier dysfunction caused by endogenous or exogenous factors can lead to various disorders such as xerosis cutis, ichthyoses, and atopic dermatitis. Filaggrin is a pivotal structural protein of the stratum corneum (SC) and provides natural moisturizing factors that play a role in skin barrier functions. Filaggrin aggregates keratin filaments, resulting in the formation of a keratin network, which binds cornified envelopes and collapse keratinocytes to flattened corneocytes. This complex network contributes to the physical strength of the skin. Filaggrin is degraded by caspase-14, calpain 1, and bleomycin hydrolases into amino acids and amino acid metabolites such as trans-urocanic acid and pyrrolidone carboxylic acid, which are pivotal natural moisturizing factors in the SC. Accordingly, filaggrin is important for the pathophysiology of skin barrier disorders, and its deficiency or dysfunction leads to a variety of skin disorders. Here, the roles and biology of filaggrin, related skin diseases, and a therapeutic strategy targeting filaggrin are reviewed. In addition, several drug candidates of different mode of actions targeting filaggrin, along with their clinical efficacy, are discussed.

Entities:  

Keywords:  Atopic dermatitis; Filaggrin; Skin barrier; Skin disorders

Year:  2021        PMID: 33462753     DOI: 10.1007/s12272-021-01305-x

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  84 in total

1.  Staphylococcus aureus colonization in atopic eczema and its association with filaggrin gene mutations.

Authors:  M-L Clausen; S M Edslev; P S Andersen; K Clemmensen; K A Krogfelt; T Agner
Journal:  Br J Dermatol       Date:  2017-09-24       Impact factor: 9.302

2.  Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration.

Authors:  Hansjörg Baurecht; Malte C Rühlemann; Elke Rodríguez; Frederieke Thielking; Inken Harder; Anna-Sophie Erkens; Dora Stölzl; Eva Ellinghaus; Melanie Hotze; Wolfgang Lieb; Sheng Wang; Femke-Anouska Heinsen-Groth; Andre Franke; Stephan Weidinger
Journal:  J Allergy Clin Immunol       Date:  2018-02-05       Impact factor: 10.793

3.  Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection.

Authors:  Caterina Barresi; Caroline Stremnitzer; Veronika Mlitz; Sanja Kezic; Arthur Kammeyer; Minoo Ghannadan; Katja Posa-Markaryan; Clare Selden; Erwin Tschachler; Leopold Eckhart
Journal:  J Invest Dermatol       Date:  2010-08-05       Impact factor: 8.551

4.  Disruption of the pelota gene causes early embryonic lethality and defects in cell cycle progression.

Authors:  Ibrahim M Adham; Mahmoud A Sallam; Gerd Steding; Monika Korabiowska; Ulrich Brinck; Sigrid Hoyer-Fender; Changkyu Oh; Wolfgang Engel
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

5.  Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

Authors:  R Bissonnette; K A Papp; Y Poulin; M Gooderham; M Raman; L Mallbris; C Wang; V Purohit; C Mamolo; J Papacharalambous; W C Ports
Journal:  Br J Dermatol       Date:  2016-09-24       Impact factor: 9.302

6.  Pyrrolidone carboxylic acid and the skin.

Authors:  E J Clar; A Fourtanier
Journal:  Int J Cosmet Sci       Date:  1981-06       Impact factor: 2.970

Review 7.  The cornified envelope: a model of cell death in the skin.

Authors:  Eleonora Candi; Rainer Schmidt; Gerry Melino
Journal:  Nat Rev Mol Cell Biol       Date:  2005-04       Impact factor: 94.444

8.  Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect.

Authors:  Sara J Brown; Karin Kroboth; Aileen Sandilands; Linda E Campbell; Elizabeth Pohler; Sanja Kezic; Heather J Cordell; W H Irwin McLean; Alan D Irvine
Journal:  J Invest Dermatol       Date:  2011-11-10       Impact factor: 8.551

Review 9.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

10.  Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27.

Authors:  Christopher G Bunick; Richard B Presland; Owen T Lawrence; David J Pearton; Leonard M Milstone; Thomas A Steitz
Journal:  J Invest Dermatol       Date:  2015-03-11       Impact factor: 8.551

View more
  6 in total

1.  Secretome of human umbilical cord mesenchymal stem cell maintains skin homeostasis by regulating multiple skin physiological function.

Authors:  Xin Wang; Qiuhong Wang; Panpan Yin; Chen Liang; Xiaohui Zhao; Dingke Wen; Yi Tan
Journal:  Cell Tissue Res       Date:  2022-10-15       Impact factor: 4.051

2.  Analysis of drug efficacy for inflammatory skin on an organ-chip system.

Authors:  Qianghua Quan; Ding Weng; Xuan Li; Quan An; Yang Yang; Bowen Yu; Yuan Ma; Jiadao Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-09-02

3.  Claudin-1 Mediated Tight Junction Dysfunction as a Contributor to Atopic March.

Authors:  Yuhan Xia; Han Cao; Jie Zheng; Lihong Chen
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

4.  Genetic Variants in Epidermal Differentiation Complex Genes as Predictive Biomarkers for Atopic Eczema, Allergic Sensitization, and Eczema-Associated Asthma in a 6-Year Follow-Up Case-Control Study in Children.

Authors:  Anna Dębińska; Hanna Danielewicz; Barbara Sozańska
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

Review 5.  Methodological Considerations for Lipid and Polar Component Analyses in Human Skin Stratum Corneum.

Authors:  E Berdyshev; I Bronova; D Y M Leung; E Goleva
Journal:  Cell Biochem Biophys       Date:  2021-07-15       Impact factor: 2.989

Review 6.  Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison.

Authors:  Tanya M Barnes; Dalibor Mijaljica; Joshua P Townley; Fabrizio Spada; Ian P Harrison
Journal:  Pharmaceutics       Date:  2021-11-26       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.